Scientists investigate why some diabetics Don't benefit from exercise
NCT ID NCT01911104
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at why some people with type 2 diabetes do not get the usual health benefits from exercise. Researchers will measure how well cells produce energy before and after exercise. The goal is to find factors that make exercise less effective for certain individuals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
84 people
The number who actually took part.
- Started
-
Oct 2013
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Type 2 Diabetes Inclusion Criteria (Group 1) * Age 30 to 65 years. * Male and Female * Type 2 diabetes determined by self-report or by a fasting glucose \> 126mg/dl * POCT HbA1c result is 5.7-8.8% or for those on anti-diabetic medications, POCT HbA1c \< 8.9% (no lower limit defined to account for those who illustrate tight glycemic control due to anti-diabetic medications). * HbA1c between 6.0% and 8.5% or for those on anti-diabetic medications, HbA1c ≤ 8.5% (no lower limit defined to account for those who illustrate tight glycemic control due to anti-diabetic medications). If a participant misses the screening HbA1c by a small margin (HbA1c ± 0.1%), the HbA1c can be repeated once. * Not involved in regular exercise program * Willing to exercise every day for the study period * If applicable, those currently taking anti-diabetic medication are taking metformin, a sulfonylurea, DPP IV inhibitor, alpha-glucosidase inhibitor, a meglitinide, colesevelam, cycloset or a SGLT2 inhibitor. Those taking 2 of these medications may proceed. * If applicable, willing to cease anti-diabetic medication use for the duration of the intervention. * BMI ≥ 22 kg/m2 Young Athletes Inclusion Criteria (Group 2) * Age 18 to 50 years * Male and Female * Engaged in a minimum of 4 cumulative hours of moderate to vigorous intensity aerobic exercise, over a minimum of 3 days per week. * BMI between 18 and 29.9 kg/m2 * VO2max \> 45 ml/min/kg BW Non-diabetes Inclusion Criteria (Group 3) * Age 30 to 65 years * Male and Female * Not involved in a regular exercise program * Willing to exercise every day for the study period * BMI ≥ 22 kg/m2 General Exclusion Criteria A=all groups, Ex=exercise group only, ND=Non-diabetes group only * Resting blood pressure ≥ 160/100 mm Hg (A) * Triglycerides \> 500 mg/dL (A) * HbA1c ≥ 6.5% (ND) * Previous or current use of an insulin pump or multiple insulin injections per day or any diabetes medications that the participant cannot refrain from for the duration of the study. (A) * Treatment with thiazolidinediones (TZDs) or GLP-1 agonists within the last 3 months. (A) * Unable or unwilling to communicate with staff or to provide written informed consent. (A) * Failure to complete baseline testing. (A) * Not physically capable of performing the exercise required of the study protocols. (Ex) * Consuming \>14 alcoholic beverages per week. (A) * Plans to be away \>2 weeks in the next 3 months. (A) * Lack of support from primary health care provider and/or family members.(Ex) * Significant weight loss in the past year (\>20 lbs) or current use of weight loss medications. (A) * Bariatric surgery or planning bariatric surgery in the next 6 months.(Ex) * Presence of clinically significant abnormalities on ECG (A) * Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the Investigator would compromise participant safety (A) * Use of drugs known to affect energy metabolism or body weight: including, but not limited to: orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc (A) * Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures. (A) * New onset (\<3 months on a stable regime) hormone replacement therapy. (A) * Current use of beta-adrenergic blocking agents (A) * Alcohol or other drug abuse (A) * Current smokers (smoking within the past 3 months) (A) * Gait problems (Ex) * Unwilling or unable to abstain from caffeine, alcohol or strenuous exercise (48h) prior to metabolic rate measurements (A) * Increased liver function tests (AST/ALT/GGT/or alkaline phosphatase greater than 2.5 times the upper limit of normal) (A) * Metal objects that would interfere with the measurement of body composition /MRS such as implanted rods, surgical clips, etc (A) * Any NYHA class of CHF (A) * Abnormal blood count/Anemia, blood transfusion or blood donation within the last 2 months. (A) * Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months (A) * Bariatric surgery or liposuction within the previous 3 years (Ex) * Cancer (active malignancy with or without concurrent chemotherapy) (A) * Rheumatoid disease (A) * Bypass graft in limb (A) * Known genetic factor (Factor V Leiden, etc) or hypercoagulable state (A) * Peripheral neuropathy, involving more than the toes (A) * Claustrophobia (A) * Major Depression (Ex) * Presence of an eating disorder or eating attitudes/behaviors that could interfere with the study completion (Ex) * Females that are currently or have been pregnant or are currently or have nursed a child within the last 12 months (A) * Presence of any condition that, in the opinion of the investigator, compromises participant safety or data integrity or the participants' ability to complete the training protocol (Ex).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Translational Research Institute for Metabolism and Diabetes
Orlando, Florida, 32804, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mindfulness and yoga rewire diabetes habits?
- Can a vegan diet delivered online help people with type 2 diabetes?
- Tiny horses, big lessons: can ponies help kids tame diabetes?
- Gut microbes in pregnancy and infancy: a window into lifelong health?
- A blood test at 50 could flag your risk of five diseases. can an app stop them?
- Chatbot coach takes aim at diabetes risk after pregnancy